These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 36690898)
1. Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein. Zhang S; Zhu R; Pan B; Xu H; Olufemi MF; Gathagan RJ; Li Y; Zhang L; Zhang J; Xiang W; Kagan EM; Cao X; Yuan C; Kim SJ; Williams CK; Magaki S; Vinters HV; Lashuel HA; Garcia BA; James Petersson E; Trojanowski JQ; Lee VM; Peng C Nat Neurosci; 2023 Feb; 26(2):213-225. PubMed ID: 36690898 [TBL] [Abstract][Full Text] [Related]
2. Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified α-Synuclein. Chen H; Zhao YF; Chen YX; Li YM ACS Chem Neurosci; 2019 Feb; 10(2):910-921. PubMed ID: 30628768 [TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Schmid AW; Fauvet B; Moniatte M; Lashuel HA Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418 [TBL] [Abstract][Full Text] [Related]
4. Posttranslational Modifications of Hassanzadeh K; Liu J; Maddila S; Mouradian MM Pharmacol Rev; 2024 Oct; 76(6):1254-1290. PubMed ID: 39164116 [No Abstract] [Full Text] [Related]
5. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications. Vicente Miranda H; Xiang W; de Oliveira RM; Simões T; Pimentel J; Klucken J; Penque D; Outeiro TF J Neurochem; 2013 Sep; 126(5):673-84. PubMed ID: 23534813 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-Synuclein in the pathogenesis of Parkinson's Disease and related disorders. Lu Y; Prudent M; Fauvet B; Lashuel HA; Girault HH ACS Chem Neurosci; 2011 Nov; 2(11):667-75. PubMed ID: 22860160 [TBL] [Abstract][Full Text] [Related]
7. Effects of α-Synuclein-Associated Post-Translational Modifications in Parkinson's Disease. He S; Wang F; Yung KKL; Zhang S; Qu S ACS Chem Neurosci; 2021 Apr; 12(7):1061-1071. PubMed ID: 33769791 [TBL] [Abstract][Full Text] [Related]
8. Implications of In Vitro Multi-Serine Phosphorylation of Alpha-Synuclein in Aggregation and Cytotoxicity. Chaturvedi M; Raj R; Yadav SK; Srivastava T; Devi S; Dharmadana D; Valéry C; Sharma SK; Kumar D; Priya S ACS Chem Neurosci; 2023 Sep; 14(17):3103-3112. PubMed ID: 37562012 [TBL] [Abstract][Full Text] [Related]
9. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels. Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787 [TBL] [Abstract][Full Text] [Related]
10. Semisynthesis and Enzymatic Preparation of Post-translationally Modified α-Synuclein. Fauvet B; Lashuel HA Methods Mol Biol; 2016; 1345():3-20. PubMed ID: 26453202 [TBL] [Abstract][Full Text] [Related]
11. Preserved proteinase K-resistant core after amplification of alpha-synuclein aggregates: Implication to disease-related structural study. Yoshinaga S; Yamanaka T; Miyazaki H; Okuzumi A; Hiyama A; Murayama S; Nukina N Biochem Biophys Res Commun; 2020 Feb; 522(3):655-661. PubMed ID: 31785806 [TBL] [Abstract][Full Text] [Related]
12. Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson's disease. Yoo H; Lee J; Kim B; Moon H; Jeong H; Lee K; Song WJ; Hur JK; Oh Y BMB Rep; 2022 Jul; 55(7):323-335. PubMed ID: 35733294 [TBL] [Abstract][Full Text] [Related]
13. Transmission of α-synuclein seeds in neurodegenerative disease: recent developments. Karpowicz RJ; Trojanowski JQ; Lee VM Lab Invest; 2019 Jul; 99(7):971-981. PubMed ID: 30760864 [TBL] [Abstract][Full Text] [Related]
14. Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson's disease. Duce JA; Wong BX; Durham H; Devedjian JC; Smith DP; Devos D Mol Neurodegener; 2017 Jun; 12(1):45. PubMed ID: 28592304 [TBL] [Abstract][Full Text] [Related]
15. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Braithwaite SP; Stock JB; Mouradian MM Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677 [TBL] [Abstract][Full Text] [Related]
16. The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson's Disease. Battis K; Xiang W; Winkler J Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686080 [TBL] [Abstract][Full Text] [Related]
17. Alpha synuclein post translational modifications: potential targets for Parkinson's disease therapy? Brembati V; Faustini G; Longhena F; Bellucci A Front Mol Neurosci; 2023; 16():1197853. PubMed ID: 37305556 [TBL] [Abstract][Full Text] [Related]
18. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates. Neupane S; De Cecco E; Aguzzi A J Mol Biol; 2023 Jun; 435(12):167930. PubMed ID: 36566800 [TBL] [Abstract][Full Text] [Related]
19. α-Synuclein arginylation in the human brain. Zhao J; Pan B; Fina M; Huang Y; Shimogawa M; Luk KC; Rhoades E; Petersson EJ; Dong DW; Kashina A Transl Neurodegener; 2022 Apr; 11(1):20. PubMed ID: 35395956 [TBL] [Abstract][Full Text] [Related]
20. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment. Kalsoom I; Wang Y; Li B; Wen H Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]